| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/ANNONC/MDT026 |
| P698 | PubMed publication ID | 23425947 |
| P50 | author | Suresh Senan | Q37830477 |
| Berend J Slotman | Q40690934 | ||
| P2093 | author name string | G Rodrigues | |
| E F Smit | |||
| A Warner | |||
| J W A Oosterhuis | |||
| D A Palma | |||
| F J Lagerwaard | |||
| C J A Haasbeek | |||
| W F van Tets | |||
| A van der Elst | |||
| J J A Joosten | |||
| M I Amir | |||
| N E Verstegen | |||
| R Mollema | |||
| P433 | issue | 6 | |
| P921 | main subject | video-assisted thoracoscopic surgery | Q4011425 |
| lung cancer | Q47912 | ||
| P304 | page(s) | 1543-1548 | |
| P577 | publication date | 2013-02-20 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis | |
| P478 | volume | 24 |
| Q40271942 | 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. |
| Q48256303 | A SUVmax-based propensity matched analysis of stereotactic body radiotherapy versus surgery in stage I non-small cell lung cancer: unveiling the role of 18F-FDG PET/CT in clinical decision-making |
| Q28079625 | A critical review of recent developments in radiotherapy for non-small cell lung cancer |
| Q37552170 | A propensity-matched analysis of surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer in the elderly |
| Q36651935 | A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II) |
| Q93347944 | A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer |
| Q38790915 | A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer |
| Q30993385 | Additional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy. |
| Q33645619 | Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy |
| Q28083924 | Challenges in the treatment of early non-small cell lung cancer: what is the standard, what are the challenges and what is the future for radiotherapy? |
| Q30570350 | Clinical outcome of hypofractionated breath-hold image-guided SABR of primary lung tumors and lung metastases. |
| Q30834087 | Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system |
| Q37060393 | Clinical outcomes of video-assisted thoracic surgery and stereotactic body radiation therapy for early-stage non-small cell lung cancer: A meta-analysis |
| Q90329536 | Comparing apples to oranges: short-term mortality after surgery versus stereotactic body radiotherapy for early-stage non-small cell lung cancer |
| Q40835700 | Comparison of Clinical Outcomes of VATS and SBRT in the Treatment of NSCLC |
| Q90277540 | Comparison of Survival After Mohs Micrographic Surgery vs Wide Margin Excision for Early-Stage Invasive Melanoma |
| Q36382039 | Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis |
| Q92407282 | Comparison of the Efficacy of Stereotactic Body Radiotherapy versus Surgical Treatment for Early-Stage Non-Small Cell Lung Cancer after Propensity Score Matching |
| Q55412836 | Editorial: Controversies in the Local Management of Lung Cancer. |
| Q61804647 | Empiric Radiotherapy for Lung Cancer Collaborative Group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation |
| Q64986638 | How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team. |
| Q49891068 | Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experience |
| Q33639144 | Impact of maximum standardized uptake value of non-small cell lung cancer on detecting lymph node involvement in potential stereotactic body radiotherapy candidates |
| Q55398195 | Implications for high-precision dose radiation therapy planning or limited surgical resection after percutaneous computed tomography-guided lung nodule biopsy using a tract sealant. |
| Q30985297 | Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data |
| Q35996052 | Improving lung cancer outcomes by improving the quality of surgical care |
| Q41673233 | Influence of an elevated nutrition risk score (NRS) on survival in patients following gastrectomy for gastric cancer |
| Q38233871 | Is stereotactic ablative radiotherapy an alternative to surgery in operable stage I non-small cell lung cancer? |
| Q37077160 | Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis |
| Q37491637 | Long-term outcomes of stereotactic body radiation therapy (SBRT) with fiducial tracking for inoperable stage I non-small cell lung cancer (NSCLC). |
| Q89635257 | Management of patients with early stage lung cancer - why do some patients not receive treatment with curative intent? |
| Q34005116 | Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada |
| Q61804649 | Medically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes |
| Q54943095 | New classification-new problems to solve. |
| Q37670432 | New techniques for assessing response after hypofractionated radiotherapy for lung cancer |
| Q35880933 | Outcomes after Stereotactic Body Radiotherapy versus Limited Resection in Older Patients with Early-Stage Lung Cancer. |
| Q48202266 | Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1). |
| Q33679694 | Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer |
| Q37739358 | Predictors of chest wall toxicity after stereotactic ablative radiotherapy using real-time tumor tracking for lung tumors |
| Q46615143 | Propensity-score-matched evaluation of the incidence of radiation pneumonitis and secondary cancer risk for breast cancer patients treated with IMRT/VMAT. |
| Q88487552 | Recent advances in the management of lung cancer |
| Q37708013 | Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer |
| Q38813253 | SABR vs. Limited Resection for Non-small Cell Lung Cancer: Are We Closer to an Answer? |
| Q35200592 | SBRT in operable early stage lung cancer patients. |
| Q42384628 | SBRT versus lobectomy in stage I NSCLC: knowns, unknowns and its interpretation |
| Q42359042 | Shared decision making in the treatment of stage I non small cell lung cancer-a choice which should equally involve both sides |
| Q38904089 | Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors |
| Q40308740 | Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer |
| Q41112569 | Stereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard |
| Q38549543 | Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a word of caution |
| Q30656342 | Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials |
| Q50096367 | Stereotactic ablative radiotherapy versus lobectomy for stage I non-small cell lung cancer: A systematic review |
| Q57172947 | Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances |
| Q35646076 | Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry |
| Q61804651 | Stereotactic body radiotherapy for centrally located stage I non-small cell lung cancer |
| Q35143839 | Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry |
| Q89870886 | Stereotactic body radiotherapy for elderly patients (≥ 75 years) with early-stage non-small cell lung cancer |
| Q33813299 | Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis |
| Q36235528 | Stereotactic body radiotherapy with helical TomoTherapy for medically inoperable early stage primary and second-primary non-small-cell lung neoplasm: 1-year outcome and toxicity analysis |
| Q28076058 | Stereotactic body radiotherapy: current strategies and future development |
| Q28085744 | Stereotactic radiotherapy for early lung cancer: Evidence-based approach and future directions |
| Q35824255 | Stereotactic radiotherapy for early stage non-small cell lung cancer |
| Q90087984 | Surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer: review of meta-analyses |
| Q86620560 | Surgery versus SABR for NSCLC |
| Q42354883 | Surgery versus SABR for early stage non-small cell lung cancer: the moving target of equipoise |
| Q59587263 | Surgery versus SABR for resectable non-small-cell lung cancer – Authors' reply |
| Q48369218 | Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. |
| Q90138365 | Survival of Primary SBRT Compared to Surgery for Operable Stage I/II Non-Small Cell Lung Cancer |
| Q47108053 | Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy - A Single Center Experience |
| Q35540262 | Thirty-day mortality underestimates the risk of early death after major resections for thoracic malignancies. |
| Q64111832 | Three discipline collaborative radiation therapy (3 DCRT ) special debate: I would treat all early‐stage NSCLC patients with SBRT |
| Q30693104 | Treatment Outcomes in Stage I Lung Cancer: A Comparison of Surgery and Stereotactic Body Radiation Therapy |
| Q47138383 | Treatment recommendations for stage I non-small cell lung cancer: does patient preference matter? |
| Q38962875 | Triaging early-stage lung cancer patients into non-surgical pathways: who, when, and what? |
| Q42410978 | Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer |
| Q92467682 | Which patients benefit most from stereotactic body radiotherapy or surgery in medically operable non-small cell lung cancer? An in-depth look at patient characteristics on both sides of the debate |
| Q88585706 | [Clinical characteristics and risk factors affecting outcomes of elderly patients with non-small cell lung cancer complicated by chronic obstructive pulmonary disease] |
| Q88208674 | [Different mortality after surgery and stereotactic body radiotherapy for early-stage non-small-cell lung cancer] |
| Q57641071 | [Local treatment of solitary intrapulmonary, malignant nodules] |
| Q55441727 | [Radiation pneumonitis after stereotactic body radiation therapy for early stage non-small cell lung cancer]. |
Search more.